France· FR:61808523
ULTOMIRIS 300 mg/3 mL, solution à diluer pour perfusion
A medicinal product containing ravulizumab, registered in France by ALEXION EUROPE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RAVULIZUMAB
- Manufacturer
- ALEXION EUROPE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550823851 flacon(s) en verre de 3 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ravulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsUltomiris 1100 mg/11 ml concentraat voor oplossing voor infusieAlexion Europe S.A.S.
- FinlandUltomirisAlexion Europe SAS
- SwedenUltomiris 1100 mg/11 ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- BelgiumUltomiris 1100 mg/11 mlAlexion Europe
- CzechiaULTOMIRISAlexion Europe SAS, Levallois-Perret
- United KingdomUltomiris 1,100mg/11ml concentrate for solution for infusion vialsAlexion Pharma UK Ltd
- United StatesUltomirisAlexion Pharmaceuticals Inc.
- CanadaULTOMIRISALEXION PHARMA GMBH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
- Norway · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d30b40a8-b228-44e6-845b-298a84b923b9 GET /v1/drugs/d30b40a8-b228-44e6-845b-298a84b923b9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61808523",
"date_amm": "2020-11-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1371",
"substance": "RAVULIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.